Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clarithromycin - film-coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clarithromycin - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - clarithromycin - prolonged-release tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - clarithromycin - film-coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - clarithromycin - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - clarithromycin - prolonged-release tablet - clarithromycin 500 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections due to susceptible organisms. such infections include: 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. clarithromycin is indicated for the prevention of disseminated mycobacterium avium complex infection in hivinfected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. clarithromycin in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer. (see further information).

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - granules for oral suspension - 125 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include o lower respiratory tract infections o upper respiratory tract infections o skin and skin structure infections o acute otitis media

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - granules for oral suspension - 250 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include: lower respiratory tract infections. upper respiratory tract infections. skin and skin structure infections. acute otitis media.

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin